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Neuroleptic Malignant Syndrome (NMS): literature
review and case series report
Julie Langan1, Daniel Martin1, Polash Shajahan2 and Daniel J Smith1*Abstract
Background: “Neuroleptic malignant syndrome” (NMS) is a potentially fatal idiosyncratic reaction to any medication
which affects the central dopaminergic system. Between 0.5% and 1% of patients exposed to antipsychotics
develop the condition. Mortality rates may be as high as 55% and many risk factors have been reported. Although
rapid escalation of antipsychotic dose is thought to be an important risk factor, to date it has not been the focus of
a published case series or scientifically defined.
Description: We aimed to identify cases of NMS and review risk factors for its development with a particular focus
on rapid dose escalation in the 30 days prior to onset. A review of the literature on rapid dose escalation was
undertaken and a pragmatic definition of “rapid dose escalation” was made. NMS cases were defined using DSM-IV
criteria and systematically identified within a secondary care mental health service. A ratio of titration rate was
calculated for each NMS patient and “rapid escalators” and “non rapid escalators” were compared. 13 cases of NMS
were identified. A progressive mean dose increase 15 days prior to the confirmed episode of NMS was observed
(241.7 mg/day during days 1–15 to 346.9 mg/day during days 16–30) and the mean ratio of dose escalation for
NMS patients was 1.4. Rapid dose escalation was seen in 5/13 cases and non rapid escalators had markedly higher
daily cumulative antipsychotic dose compared to rapid escalators.
Conclusions: Rapid dose escalation occurred in less than half of this case series (n = 5, 38.5%), although there is
currently no consensus on the precise definition of rapid dose escalation. Cumulative antipsychotic
dose – alongside other known risk factors - may also be important in the development of NMS.
Keywords: Neuroleptic malignant syndrome, NMS, Rapid dose escalation, Rapid dose titration, AntipsychoticsBackground
“Neuroleptic malignant syndrome” (NMS) derives from
the French “syndrome malin des neuroleptiques” and
was first described in 1960 by Delay [1] and colleagues
in association with haloperidol. It is a potentially fatal
idiosyncratic reaction to any medication which affects
the central dopaminergic system, most commonly anti-
psychotics, with between 0.5% and 1% of patients
exposed to these drugs developing the condition [2]. It is
thought that all antipsychotics are capable of causing
NMS, including the newer atypical agents, with case* Correspondence: daniel.smith@glasgow.ac.uk
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reproduction in any medium, provided the orreports of clozapine [3], risperidone [4] and olanzapine
[5] all causing NMS. Patients with suspected NMS usu-
ally have a history of anti-psychotic exposure; however
this may not always be the case. The anti-emetic meto-
clopramide [6,7] the tricyclic antidepressant amoxapine
[8], lithium [9] and phenelzine [10] have all been
reported to cause NMS, presumably as a result of their
dopamine blocking properties.
The precise pathophysiology of NMS remains unknown.
It has been suggested that a marked and sudden reduction
in central dopaminergic activity resulting from D2 receptor
blockade within the nigrostriatal, hypothalamic, mesolim-
bic and mesocortical pathways may help to explain some
of the clinical features of NMS such as rigidity, hyperther-
mia and altered mental state [11,12] This suggestion is sup-
ported by a number of factors including the observationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cases of NMS and the observation that NMS can also be
induced by the abrupt withdrawal of dopamine.
However, D2 receptor antagonism does not fully explain
all the signs and symptoms of NMS. In particular the oc-
currence of NMS with medications with low D2 affinity
has led to the proposal that sympathoadrenal hyperactivity
resulting from the removal of tonic inhibition within the
sympathetic nervous system may play an important role in
NMS [13]. This is supported by the frequent occurrence
of autonomic symptoms in NMS, as well as demonstrated
changes in urine and plasma catecholamine levels. Similar-
ities with malignant hyperthermia have led to theories that
a defect in calcium regulatory proteins within sympathetic
neurons may be the key factor that triggers the onset of
NMS [14]. Release of calcium from the sarcoplasmic
reticulum of muscle cells has been shown to be increased
with antipsychotic usage [15] and it may be that this could
lead to the rigidity, muscle breakdown and hyperthermia
seen in NMS.
Diagnosis of NMS is largely based on clinical history
and the presence of specific clinical signs. Classically,
NMS has been characterized by a triad of fever, rigidity
and altered mental state [12]. However it is becoming in-
creasingly clear that the presentation may be heteroge-
neous and this is reflected in the current DSM IV criteria
(Table 1). Many conditions can mimic the presentation of
NMS, including heat stroke, CNS infections, toxic enceph-
alopathies, agitated delirium and more benign drug
induced extra-pyramidal symptoms [12]. Given the clinical
heterogeneity diagnostic uncertainty may occur. It isTable 1 DSM IV Research criteria for neuroleptic
malignant syndrome
A. Development of severe muscle rigidity and elevated temperature
associated with the use of neuroleptic medication
B. Two (or more) of the following
a. diaphoresis,
b. dysphagia,
c. tremor,
d. incontinence,
e. changes in level of consciousness (ranging from confusion to coma),
f. mutism,
g. tachycardia,
h. elevated or labile blood pressure,
i. leukocytosis
j. Laboratory evidence of muscle injury (e.g. elevated CPK
creatinine phosphokinase).
C. The symptoms in criteria A and B are not due to another substance,
neurological or general medical condition
D. The symptoms in A and B are no better accounted for by a mental
disorderimperative that any underlying source of infection in par-
ticular is excluded and consequentially patients may be ex-
tensively investigated with serial blood and urine cultures,
chest X ray, neuro-imaging and CSF analysis being
obtained before underlying infections can confidently be
excluded. A high level of clinician suspicion, vigilance and
expertise is required in order to diagnose and initiate
treatment of NMS promptly.
A number of risk factors have been identified through
several case control studies [16-22]. Rapid alteration and
in particular escalation of anti-psychotic dose has
emerged as an important risk factor for the development
of NMS [16], with most cases occurring shortly after ini-
tial exposure [19]. NMS is less likely to occur in patients
who have been stable on their dose of antipsychotic
medication for a long time or who have good long-term
compliance [20,23]. Antipsychotic polypharmacy, con-
comitant use of medications which predispose to NMS
(including lithium) [24] and the use of intramuscular
medication [21,22] all increase the risk of NMS. Other
risk factors including agitation, dehydration, physical ex-
haustion, malnutrition, hyponatremia, thyrotoxicosis, al-
cohol or other psychoactive substance misuse [25] are
all thought to be important in NMS. The presence of an
organic brain syndrome or previous brain injury [20],
poorly-controlled antipsychotic-induced extra pyramidal
side effects (EPSEs) and iron deficiency [26] have also
found to increase the risk of NMS. Males under 40 are
often considered to be at greater risk of NMS but it is
unclear if this is a reflection of increased use of antipsy-
chotics within this population. Postpartum women may
be at slightly elevated risk [27] and although family clus-
tering [28] has been reported, there have been no studies
to date investigating genetic vulnerability to NMS.
Rate of dose escalation of antipsychotic medication
has been recognized as a risk factor for NMS [29]. Rate
of patient titration onto a therapeutic dose is often
multifactorial, with factors such as age, co-morbid phys-
ical health problems, previous antipsychotic exposure,
history of side effects, severity of illness and the need for
a rapid clinical response being important considerations
[30]. Individual clinician preference and experience also
plays a role. There are titration schedules available for
certain medications, most notably quetiapine [31] and
clozapine; however guidance is not available for all med-
ications. In clinical practice there are occasions where
antipsychotic dose is escalated more quickly than would
be seen routinely. This practice is often termed “rapid
dose escalation”. However there is no consensus on what
rate of escalation would be defined as “rapid” and to
date no mathematical calculation to quantify and com-
pare such dose escalations has been considered.
NMS remains an uncommon, idiosyncratic and poten-
tially fatal complication of antipsychotic medication.
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NMS, to our knowledge there have been no reports to
date which specifically focus on patterns of antipsychotic
dosing in the days leading up to an episode of NMS and
no attempts to define “rapid dose escalation”.
Construction and content
We aimed to systematically identify all cases of NMS
within a defined UK health service population (NHS
Lanarkshire, Scotland) and review potential risk factors
with a focus on changes in antipsychotic dose in the
30 days prior to development of the syndrome. We com-
pared this dosing to routine in-patient clozapine titra-
tion schedules and the dosing schedule for quetiapine.
Based on our findings and review of the literature, we
also aimed to define “rapid dose escalation”.
Literature review
We reviewed the literature surrounding NMS using the
most commonly searched databases including PubMed,
Google scholar and Medline using keywords including
“NMS” and “neuroleptic malignant syndrome”. We
searched for a definition of rapid dose escalation using
keywords “antipsychotic”, “neuroleptic”, “rapid dose escal-
ation”, “rapid titration”, and “rapid increase”. We included
case reports, case series, and systematic reviews.
Systematic identification of NMS cases
This study was approved by local NHS research ethics
committee and Research and Development committee
(Ref 11/WS/0073). We conducted a retrospective analysisRecords suggesting possibility 
of NMS via electronic search  
n=303
Medical & psychiatric case 
notes requested n= 28 
NMS cases confirmed by DSM 
IV cri teria n=13
Total  number of records on 
Genysis n= 416,708
Figure 1 Identification procedure for NMS cases.of all psychiatric contacts in a discrete geographical area
in Scotland (NHS Lanarkshire, population 550,000) to sys-
tematically identify cases of NMS (recorded during the
period 2002–2011). The electronic records assessed cover
all secondary care psychiatric contacts and were phased
into NHS Lanarkshire’s mental health service over the
period 2002–2005 (the ‘Genysis’ database).
We searched for cases using the key words “neuroleptic
malignant syndrome”, “NMS”, and “high CK”. Once pos-
sible cases were identified, the electronic record was ini-
tially reviewed by JL and DM. If there was a suggestion of
NMS the psychiatric cases notes and, where appropriate,
the general medical records were requested and reviewed
independently by 2 psychiatrists (JL & DM) (Figure 1).
Cases of NMS were identified using DSM-IV criteria
(Table 1), namely documented evidence of pyrexia and
muscular rigidity in association with antipsychotic use.
In the absence of both pyrexia and muscular rigidity, 2
or more of the following features were required to be
documented in the notes - diaphoresis, dysphagia,
tremor, incontinence, changes in level of consciousness
(ranging from confusion to coma), mutism, tachycardia,
elevated or labile blood pressure, leukocytosis or evi-
dence of muscle injury (elevated CK). We required the
symptoms seen not to be due to another substance,
neurological or general medical condition. Any potential
disagreement in diagnosis between authors was dis-
cussed and a consensus was reached.
Demographic details, information regarding predis-
posing risk factors for NMS and the episode of NMS
were described and a detailed 30 day antipsychotic doseExcluded as no evidence of 
NMS based on electronic key 
Excluded as no evidence of NMS 
based on detailed electronic 
case record review n=275
Excluded as not fulfilling DSM 
IV diagnostic cri teria for NMS 
n=15
word search n= 416,405
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A cumulative antipsychotic dose was calculated using
chlorpromazine equivalence to allow comparison and
an estimation of total cumulative dose of antipsychotic
(See Table 2). The antipsychotic dose trajectories gen-
erated were compared to the inpatient titration sched-
ule for clozapine used in the UK and the quetiapine
dosing schedules in the British National Formulary
(BNF).
The cumulative antipsychotic dose for each NMS pa-
tient was calculated for days 1 to 15 and days 16 to 30
and a ratio of ‘first 15 days’ to ‘second 15 days’ dose was
generated. We then sub-categorized the NMS cohort
into “rapid dose escalators” and “non rapid dose escala-
tors” based on the ratio calculated. We defined rapid
dose escalators as individuals who had at least a 4 times
increase in their ratio of cumulative dose at days 16–30
compared to days 1–15. This conservative threshold was
chosen pragmatically because a clozapine ratio of 3 dur-
ing the first and second halves of a titration schedule is
deemed standard practice and has a license to be titrated
in this way. Quetiapine also has titration schedules
recommended in the BNF [31] for both acute mania and
schizophrenia and the ratio during the first and second
halves of its titration schedule is 3.0 and 3.4 respectively.
The two groups were then compared in terms of demo-
graphics, risk factors, clinical features and secondary
complications.Discussion
We identified 13 cases of NMS: 7 were male (53.8%) and
the average age was 46.2 years (range 19.4-70.7 years)
(Table 3). The most common ICD 10 diagnosis was F20
Schizophrenia, schizotypal and delusional disorders diag-
nosis (n = 7, 53.8%) followed by F30 Mood (Affective)
Disorders (2 n = 3, 3.1%). Other diagnoses included F0
Organic Mental Disorders (n = 2, 15.4%) and F60Table 2 Antipsychotic chlorpromazine equivalents
Medication (mg) Chlorpromazine Equivalence (mg)
Chlorpromazine 100 100
Quetiapine 133.3 100
Amisulpiride 100 100
Olanzapine 5 100
Aripiprazole 7.5 100
Risperidone 2 100
Clozapine 200 100
Haloperidol 3 100
Sulpiride 200 100
ClopixolAccuphase
(zuclopenthixol acetate) 100
100Disorders of Adult Personality & Behaviour (n = 1, 7.7%).
Additional clinical features of the NMS cases are out-
lined in Table 3.
In terms of diagnostic features of NMS, the most com-
monly seen features were raised CK (100% of cases where
a CK was documented (n = 12)), altered GCS (n = 12,
92.3%), tachycardia (n = 11, 84.6%) and rigidity (n = 10,
76.9%). Pyrexia was documented in 5 cases (38.5%).
Only 5 patients (38.5%) presented with the classic triad
of rigidity, hyperthermia and altered conscious level
(Table 4).
Those who were not considered “rapid dose escalators”
were more likely to have BP instability, diaphoresis and in-
continence compared to those who underwent “rapid dose
escalation”. The mean CK value was higher in those who
underwent standard dose titration and had high cumula-
tive antipsychotic dose compared to those who under-
went “rapid dose escalation” (2678.3U/l vs. 1687.2U/l)
[Table 4].
All patients at minimum had a full physical examin-
ation undertaken to exclude underlying infection and
had renal function, full blood count and inflammatory
markers obtained. The majority of cases (n = 11, 84.6%)
underwent neuro-imaging with 3 (23.1%) undergoing
CSF examination.
All patients had their antipsychotic medication
stopped when suspicion of NMS was raised by the clin-
ical team and were commenced on IV fluids. 76.9% of
patients (n = 10), required transfer to an acute medical
ward where duration of stay varied from one to fifteen
days. Two patients (15.4%) were treated with dantrolene,
one (7.7%) with combination dantrolene and bromocrip-
tine and one (7.7%) with ECT. Two patients (15.4%) had
documented evidence of seizure activity during their epi-
sode of illness, one (7.7%) developed a DVT, one (7.7%)
deranged LFTs and four (30.8%) developed acute renal
failure.
Medications
Table 5 describes in detail the medications received dur-
ing the 30 days prior to NMS onset. Antipsychotic poly-
pharmacy rates where high (7 cases, 53.8%), as was the
use of parenteral medication (5 cases 38.5%).
Figure 2 shows each individual’s antipsychotic dose
trajectories 30 days prior to the onset of NMS. All anti-
psychotic dosages were calculated as chlorpromazine
equivalents.
Figure 3 shows the mean antipsychotic dose pattern
for all 13 cases over the 30 days prior to NMS onset, the
mean antipsychotic dose pattern minus patient 7 for the
30 days prior to NMS onset, the inpatient clozapine ti-
tration schedule and the quetiapine titrations schedules.
In terms of patterns of prescribing, mean daily dose in
the NMS cohort increased over the 30 day period- from
Table 3 Clinical & demographic details
NMS patients
(n = 13)
Cases 1–5 “rapid dose
escalators” (n = 5)
Cases 6–13 “non rapid
dose escalators”
(n = 8)
Mean age, years [95% C.I.] 46.2 47.8 45.2
Male, n (%) 7 (53.8) 2 (40) 5 (62.5)
ICD 10 Diagnosis
F20 Schizophrenia n (%) 7 (53.8) 2 (40) 5 (62.5)
F30 Affective Disorders n (%) 3 (23.1) 2 (40) 1 (12.5)
F0 Organic Mental Disorder n (%) 2 (15.4) 0 (0) 2 (25)
F60 Disorder of Adult Personality & Behaviour n (%) 1 (7.7) 1 (20) 0 (0)
History of alcohol misuse, n (%) 5 (38.5) 2 (40) 3 (37.5)
History of substance misuse, n (%) 4 (30.8) 1 (20) 3 (37.5)
Compulsory Treatment, n (%) 5 (38.5) 2 (40) 3 (37.5)
History of non compliance, n (%) 9 (69.2) 3 (60) 6 (75)
Antipsychotic naïve, n (%) 1 (7.7) 1 (20) 0 (0)
History of extra pyramidal side effects, n (%) 8 (61.5) 2 (40) 6 (75)
Co prescribed oral antidepressant, n (%) 3 (23.1) 2 (40) 1 (12.5)
Co prescribed lithium, n (%) 2 (15.4) 1 (20) 1 (12.5)
Received IM medication, n (%) 5 (38.5) 2 (40) 3 (37.5)
Antipsychotic polypharmacy, n (%) 7 (53.8) 2 (40) 5 (62.5)
Required physical restraint, n (%) 5 (38.5) 2 (40) 3 (37.5)
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days 16–30. The mean ratio of dose escalation for NMS
patients was 1.4.
In terms of “rapid dose escalation”, cases 1 to 5 received
a greater than 4 times increase in their mean daily dose
from days 1–15 (34.2 mg/day) compared to days 16–30
(281.3 mg/day). The mean cumulative dose for days 1–15
was 512.4 mg compared to 4219.9 mg for days 16–30.Table 4 Diagnostic features of NMS
Documented
diagnostic feature
of NMS
All NMS
patients
(n = 4)
Cases 1–5
“rapid dose
escalators”
(n = 5)
Cases 6–13
“non rapid dose
escalators”
(n = 8)
Pyrexia n (%) 5 (38.5) 1 (20) 4 (50)
Muscle Rigidity n (%) 10 (76.9) 3 (60) 7 (87.5)
Elevated CK n (%) 12 (100)1 4 (100)1 8 (100)
Mean CK U/l 2343.0 1672.5 2678.3
Altered GCS n (%) 12 (92.3) 4 (80) 8 (100)
Tachycardia n (%) 11 (84.6) 5 (100) 6 (75)
Mutism n (%) 7 (53.8) 2 (40) 5 (62.5)
Labile BP n (%) 6 (46.1) 1 (20) 5 (62.5)
Diaphoresis n (%) 8 (61.5) 2 (40) 6 (75)
Incontinence n (%) 6 (46.2) 1 (20) 5 (62.5)
Tremor n (%) 3 (23.1) 1 (20) 2 (25)
1information missing (diagnosed based on other criteria).For the “non rapid dose escalators”, the mean daily
antipsychotic dose for days 1–15 and days 16–30 was
markedly higher than that seen in both the “rapid dose
escalator” cohort and the clozapine titration cohort.
(406.8 mg/day vs. 34.2 mg/day vs. 63.8 mg/day during
days 1–15 and 387.8 mg/day vs. 281.3 mg/day vs.
185.7 mg/day during days 16–30) (Table 6). The cumu-
lative dose for the “non rapid dose escalators was also
markedly higher (6102.5 mg for”non rapid escalators” vs.
512.4 mg for the “rapid escalators” vs. 893.8 mg for clo-
zapine titrators in the first 15 days and 5817.2 mg for”-
non rapid escalators” vs. 4219.9 mg for the “rapid
escalators” vs. 2600 mg for clozapine titrators during
days 16–30) (Table 6).
Risk factors for NMS
High titration rates of antipsychotics have been identi-
fied as a potential risk factor for the development of
NMS and our study partially supports this observation.
In our study, patients who developed NMS, a progres-
sive mean dose increase 15 days prior to the confirmed
diagnosis of NMS was observed. Considering NMS cases
on an individual basis, not all received an increase in
their antipsychotic dose. When compared to the known
titration schedules, not all NMS patients were titrated at
a higher rate - in fact only five patients (38.5%) were
titrated at an elevated rate. In terms of cumulative anti-
psychotic dose received over the 30 day period, nine
Table 5 Antipsychotics prescribed within 30 days of NMS
Patient Antipsychotics prescribed within 30 days of NMS
1 PRN Haloperidol
2 Risperidone & chlorpromazine
3 Olanzapine & PRN haloperidol
4 Quetiapine
5 Switched from clozapine to amisulpiride
6 Retitrated on clozapine & PRN haloperidol
7 Clozapine & amisulpiride combination treatment
Purposeful overdose of clozapine. All antipsychotic stopped.
Given sulpiride, haloperidol and accuphase
8 Olanzapine & PRN haloperidol
9 Switched from aripiprazole to risperidone & PRN
chlorpromazine
10 Quetiapine & haloperidol
11 Risperidone
12 Quetiapine
13 Switched from olanzapine to amisulpiride
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duals being titrated on clozapine. Four patients (30.8%)
received a lower total dose- of those receiving a lower
cumulative dose; two were rapid escalators and two non
rapid escalators.
Rapid dose escalation
Rapid dose escalation, although a recognized clinical
phenomenon, has not been systematically defined. There
are case reports of rapid dose titrations occurring safely,
however these involved small numbers of acutely unwell
patients, being titrated on quetiapine [29] and olanzapineAntipsychotic Dose Escalat
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Figure 2 30 day antipsychotic dose trajectory for NMS cases 1–13. NB
allow ease of graph interpretation).[30]. In these studies, “rapid dose escalation” was defined
when patients received either a higher total dose of anti-
psychotic medication (olanzapine 30 mg- 40 mg or quetia-
pine 900 mg-1200 mg) or were more rapidly titrated onto
quetiapine than is recommended by the BNF. However
the titration rates of the patients included in the study
were variable and in some antipsychotic polypharmacy oc-
curred. No cumulative dose for patients was calculated
and no mathematical attempt was made to quantify the
“rapid dose escalation” described.
To date, our study is the only one available whereby an
attempt to define rapid dose escalation mathematically
based on comparison of cumulative dose over two time
periods has occurred. This method allows comparison of
dose escalation not only between different antipsychotics
but also over different periods of time of titration. Provided
doses are converted to chlorpromazine equivalents and cu-
mulative doses over the first half of the titration schedule
are compared to the second half, a ratio of dose escalation
can be calculated. The individual dose escalation rate can
then be compared to standard practice seen for clozapine
and quetiapine allowing a more scientific evaluation of
dose titration to be made. This method although limited
by comparison only to standardised UK titration schedules,
represented the best way to pragmatically define rapid dose
escalation.
Our study suggests that a rapid rate of anti-psychotic
dose escalation, although likely to be an important risk
factor, is not universally observed in cases of NMS. Cumu-
lative dose of antipsychotic may be equally important. It is
worth noting that mean daily and mean cumulative anti-
psychotic doses were markedly higher both at day 15 and
day 30 in the non rapidly escalating NMS cohort com-
pared to the cohort who underwent rapid escalation.ion 30 Days prior to NMS
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higher peak mean CK value during their episode of NMS.
Diagnosis of NMS
The heterogeneous presentation of NMS is reflected in
the current DSM IV criteria (Table 1), and our study
supports observations of this. In our cohort, elevated
CK, altered GCS and tachycardia were the most fre-
quently documented features of NMS. Only five cases
(38.5%), presented with the classic triad of rigidity,
hyperthermia and altered conscious level. However given
the entire clinical picture of our cases, their response to
treatment combined with the fact 2 independent psy-
chiatrists (JL & DM) reviewed the cases, we are
confident that despite the heterogenic presentation they
represent true NMS cases.
There have been some reports of NMS induced by
second generation antipsychotics, having a propensity
for atypical clinical presentations. However a recent
comparison of NMS induced by first and second gener-
ation antipsychotics suggested that the clinical profile is
“largely similar” [32]. It did recognize that that “cloza-
pine induced NMS. . . (could be) differentiated by the
relative lack of rigidity as a feature”. However interest-
ingly in our cohort all patients who were exposed to clo-
zapine in the 30 day period prior to their episode ofTable 6 Mean antipsychotic dose prescribed
NMS patient
(n = 13)
Mean cumulative total antipsychotic dose (mg) Days 1-15 3625.1
Mean daily antipsychotic dose (mg) Days 1-15 241.7
Mean cumulative total antipsychotic dose (mg) Days 16-30 5202.8
Mean daily antipsychotic dose (mg) Days 16-30 346.9
Mean Ratio (Days 16–30: Days 1–15) 1.4NMS were noted to have rigidity as a feature of their
presentation. This highlights the importance of a high
level of clinician suspicion, vigilance and the importance
of repeated review and reassessment in order to diag-
nose and initiate treatment of NMS promptly.
Conclusions
Prescribers should be vigilant with regards to dose escal-
ation of all psychotropic medications, particularly anti-
psychotics. Our study although limited by its small
sample size and retrospective nature represents a prag-
matic attempt to review antipsychotic dose escalation as
a trigger for NMS. To our knowledge this is the only
case series primarily focusing on antipsychotic dose es-
calation as a potential trigger for NMS and the first to
attempt to define “rapid dose escalation” mathematically.
The heterogeneity of the condition, combined with its
rarity makes NMS difficult to research. Our case series
reflects the complexity of the condition and by its retro-
spective nature allows it to be practicable to current
clinical practice and adds to the limited evidence basis
available.
Our findings indicate that it is not easy to predict what
rate of antipsychotic dose escalation (if any) will result
in the development of NMS. Indeed, the rate of dose es-
calation amongst less than half the cases (5 cases 38.5%)s Cases 1–5 “rapid dose
escalators” (n = 5)
Cases 6–13 “non rapid
dose escalators” (n = 8)
Clozapine
titration
512.4 6102.5 893.8
34.2 406.8 63.8
4219.9 5817.2 2600
281.3 387.8 185.7
7.3 1.1 2.9
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was less than that seen in standard practice of titration
with clozapine and quetiapine. Our findings also indicate
that prescribers should also be mindful of cumulative
antipsychotic dose and be aware of prescribing large
doses of medication over prolonged periods of time.
It is clear that more work on both the heterogeneous
presentation of NMS and its aetiology (both antipsychotic-
related and other related factors) is warranted. A detailed
review of a large series of patients with NMS (perhaps
recruited internationally) matched to controls, with a par-
ticular focus on cumulative antipsychotic dose as well as
rate of dose escalation, would be helpful in order to further
enhance understanding of this condition. This may also
allow a more scientific definition of “rapid dose escalation”
to be determined.
Abbreviation
NMS: Neuroleptic Malignant Syndrome.
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